Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter

Agnes Basseville, Akina Tamaki, Caterina Ierano, Shana Trostel, Yvona Ward, Robert W. Robey, Ramanujan S. Hegde, Susan E. Bates

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Histone deacetylase inhibitors (HDI) have exhibited some efficacy in clinical trials, but it is clear that their most effective applications have yet to be fully determined. In this study, we show that HDIs influence the expression of a common polymorphic variant of the chemotherapy drug efflux transporter ABCG2, which contributes to normal tissue protection. As one of the most frequent variants in human ABCG2, the polymorphism Q141K impairs expression, localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity. Mechanistic investigations revealed that the ABCG2 Q141K variant was fully processed but retained in the aggresome, a perinuclear structure, where misfolded proteins aggregate. In screening for compounds that could correct its expression, localization, and function, we found that the microtubule-disrupting agent colchicine could induce relocalization of the variant from the aggresome to the cell surface. More strikingly, we found that HDIs could produce a similar effect but also restore protein expression to wild-type levels, yielding a restoration of ABCG2-mediated specific drug efflux activity. Notably, HDIs did not modify aggresome structures but instead rescued newly synthesized protein and prevented aggresome targeting, suggesting that HDIs disturbed trafficking along microtubules by eliciting changes in motor protein expression. Together, these results showed how HDIs are able to restore wild-type functions of the common Q141K polymorphic isoform of ABCG2. More broadly, our findings expand the potential uses of HDIs in the clinic.

Original languageEnglish
Pages (from-to)3642-3651
Number of pages10
JournalCancer Research
Volume72
Issue number14
DOIs
Publication statusPublished - Jul 15 2012

Fingerprint

Histone Deacetylase Inhibitors
Drug Therapy
Microtubules
Pharmaceutical Preparations
Proteins
Colchicine
Protein Isoforms
Clinical Trials
ATP Binding Cassette Transporter, Sub-Family G, Member 2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. / Basseville, Agnes; Tamaki, Akina; Ierano, Caterina; Trostel, Shana; Ward, Yvona; Robey, Robert W.; Hegde, Ramanujan S.; Bates, Susan E.

In: Cancer Research, Vol. 72, No. 14, 15.07.2012, p. 3642-3651.

Research output: Contribution to journalArticle

Basseville, Agnes ; Tamaki, Akina ; Ierano, Caterina ; Trostel, Shana ; Ward, Yvona ; Robey, Robert W. ; Hegde, Ramanujan S. ; Bates, Susan E. / Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter. In: Cancer Research. 2012 ; Vol. 72, No. 14. pp. 3642-3651.
@article{d695d688b5624416bea91d85a60ad11b,
title = "Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter",
abstract = "Histone deacetylase inhibitors (HDI) have exhibited some efficacy in clinical trials, but it is clear that their most effective applications have yet to be fully determined. In this study, we show that HDIs influence the expression of a common polymorphic variant of the chemotherapy drug efflux transporter ABCG2, which contributes to normal tissue protection. As one of the most frequent variants in human ABCG2, the polymorphism Q141K impairs expression, localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity. Mechanistic investigations revealed that the ABCG2 Q141K variant was fully processed but retained in the aggresome, a perinuclear structure, where misfolded proteins aggregate. In screening for compounds that could correct its expression, localization, and function, we found that the microtubule-disrupting agent colchicine could induce relocalization of the variant from the aggresome to the cell surface. More strikingly, we found that HDIs could produce a similar effect but also restore protein expression to wild-type levels, yielding a restoration of ABCG2-mediated specific drug efflux activity. Notably, HDIs did not modify aggresome structures but instead rescued newly synthesized protein and prevented aggresome targeting, suggesting that HDIs disturbed trafficking along microtubules by eliciting changes in motor protein expression. Together, these results showed how HDIs are able to restore wild-type functions of the common Q141K polymorphic isoform of ABCG2. More broadly, our findings expand the potential uses of HDIs in the clinic.",
author = "Agnes Basseville and Akina Tamaki and Caterina Ierano and Shana Trostel and Yvona Ward and Robey, {Robert W.} and Hegde, {Ramanujan S.} and Bates, {Susan E.}",
year = "2012",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-11-2008",
language = "English",
volume = "72",
pages = "3642--3651",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter

AU - Basseville, Agnes

AU - Tamaki, Akina

AU - Ierano, Caterina

AU - Trostel, Shana

AU - Ward, Yvona

AU - Robey, Robert W.

AU - Hegde, Ramanujan S.

AU - Bates, Susan E.

PY - 2012/7/15

Y1 - 2012/7/15

N2 - Histone deacetylase inhibitors (HDI) have exhibited some efficacy in clinical trials, but it is clear that their most effective applications have yet to be fully determined. In this study, we show that HDIs influence the expression of a common polymorphic variant of the chemotherapy drug efflux transporter ABCG2, which contributes to normal tissue protection. As one of the most frequent variants in human ABCG2, the polymorphism Q141K impairs expression, localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity. Mechanistic investigations revealed that the ABCG2 Q141K variant was fully processed but retained in the aggresome, a perinuclear structure, where misfolded proteins aggregate. In screening for compounds that could correct its expression, localization, and function, we found that the microtubule-disrupting agent colchicine could induce relocalization of the variant from the aggresome to the cell surface. More strikingly, we found that HDIs could produce a similar effect but also restore protein expression to wild-type levels, yielding a restoration of ABCG2-mediated specific drug efflux activity. Notably, HDIs did not modify aggresome structures but instead rescued newly synthesized protein and prevented aggresome targeting, suggesting that HDIs disturbed trafficking along microtubules by eliciting changes in motor protein expression. Together, these results showed how HDIs are able to restore wild-type functions of the common Q141K polymorphic isoform of ABCG2. More broadly, our findings expand the potential uses of HDIs in the clinic.

AB - Histone deacetylase inhibitors (HDI) have exhibited some efficacy in clinical trials, but it is clear that their most effective applications have yet to be fully determined. In this study, we show that HDIs influence the expression of a common polymorphic variant of the chemotherapy drug efflux transporter ABCG2, which contributes to normal tissue protection. As one of the most frequent variants in human ABCG2, the polymorphism Q141K impairs expression, localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity. Mechanistic investigations revealed that the ABCG2 Q141K variant was fully processed but retained in the aggresome, a perinuclear structure, where misfolded proteins aggregate. In screening for compounds that could correct its expression, localization, and function, we found that the microtubule-disrupting agent colchicine could induce relocalization of the variant from the aggresome to the cell surface. More strikingly, we found that HDIs could produce a similar effect but also restore protein expression to wild-type levels, yielding a restoration of ABCG2-mediated specific drug efflux activity. Notably, HDIs did not modify aggresome structures but instead rescued newly synthesized protein and prevented aggresome targeting, suggesting that HDIs disturbed trafficking along microtubules by eliciting changes in motor protein expression. Together, these results showed how HDIs are able to restore wild-type functions of the common Q141K polymorphic isoform of ABCG2. More broadly, our findings expand the potential uses of HDIs in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84863883943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863883943&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2008

DO - 10.1158/0008-5472.CAN-11-2008

M3 - Article

C2 - 22472121

AN - SCOPUS:84863883943

VL - 72

SP - 3642

EP - 3651

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 14

ER -